JM-010 is under clinical development by Contera Pharma and currently in Phase II for Dyskinesia. According to GlobalData, Phase II drugs for Dyskinesia have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JM-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JM-010 overview
JM-010 (CTP-010) is under development for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease. The drug candidate is a fixed-dose combination of two approved products in a proprietary formulation. The drug candidate is administered by the oral route. It acts by targeting several serotonin 5-HT receptors, including 5-HT1A, 5-HT1D, 5-HT1B, and 5-HT1F receptors. The drug candidate is developed based on a poly-pharmacological approach.
Contera Pharma overview
Contera Pharma that engaged in identifying and developing innovative treatments for patients suffering from movement disorders. The company is headquartered in Copenhagen, Hovedstaden, Denmark.
For a complete picture of JM-010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
